This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of …

This herein described TATCIST study was designed to confirm the safety and efficacy results of 225Ac-PSMA-I&T (renamed FPI-2265) to results published to date. Figure 1. Chemical …

Apr 9, 2024 · Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who …

Fusion’s lead program, FPI-2265, is evaluating 225 Ac-PSMA I&T, a small molecule targeting PSMA expressed in prostate cancers. The alpha-emitting radiopharmaceutical is being …

The article focuses on Actinium-225 FPI-2265 (225 Ac-PSMA-I&T), a novel radiopharmaceutical for treating metastasised castration-resistant prostate cancer (mCRPC). It targets PSMA, …

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

May 10, 2024 · FPI-2265, an actinium-225-based PSMA which targets RC, is being explored in a phase 2 trial for the treatment of patients with mCRPC. Actinium-225, with its emission of …

May 9, 2024 · FPI-2265 is an actinium-225 based PSMA targeting RC, for mCRPC, currently in a Phase 2 trial. Actinium-225 emits alpha particles and holds the promise of being a next …

Mar 19, 2024 · FPI-2265 targets prostate-specific membrane antigen (PSMA), a protein that is highly expressed in mCRPC, and is currently in a Phase II trial. The acquisition brings new …

Apr 5, 2024 · Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225 Ac-PSMA-I&T) for the treatment of metastatic …